Lilly olomorasib ESMO 2026 results show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer. The data cover olomorasib with pembrolizumab, with or without chemotherapy. Lilly expects first randomized Phase 3 SUNRAY-01 data in the first half of 2027.
Johnson & Johnson will present more than 25 solid tumor abstracts at ESMO 2026, led by the first JNJ-6143 RIPTAC readout in prostate cancer, new RYBREVANT FASPRO head and neck data and ERLEADA PROTEUS findings.
Lilly Sofe-M, an investigational FRα-targeting antibody-drug conjugate, combined with bevacizumab produced a 79.3% confirmed objective response rate and 100% disease control in platinum-sensitive ovarian cancer in Phase 1 data, to be presented orally at ESMO 2026 in Madrid.
TEZSPIRE Eosinophilic Esophagitis results from the Phase 3 CROSSING trial show histologic remission and dysphagia improvement at week 24, sustained through week 52, Amgen and AstraZeneca announced on October 20, 2026.
The Merck oncology pipeline will present first-time Phase 3 results for intismeran autogene plus KEYTRUDA, sacituzumab tirumotecan and KEYTRUDA monotherapy in Madrid from Oct. 23-27, 2026, alongside more than 90 additional abstracts.
New post-hoc analyses from Eli Lilly show Lilly Omvoh (mirikizumab-mrkz) helped 27.7% of ulcerative colitis patients reach comprehensive disease control and 20.4% of Crohn’s disease patients reach corticosteroid-free deep remission at one year, including patients with prior biologic failure.
Charles River Laboratories and Magellan Stem Cells announced a collaboration on Oct. 13, 2026, bringing cGMP next-generation sequencing viral safety testing to Zelestrocel, Magellan’s off-the-shelf osteoarthritis stem cell therapy candidate.
IQVIA and Veeva Systems have expanded their partnership. IQVIA Veeva clinical operations now includes Veeva CTMS, eTMF, Study Startup and Site Connect as enterprise standard applications across IQVIA clinical development studies, extending the earlier EDC partnership.
Regeneron Pasatru (garetosmab-grts) showed no new heterotopic ossification lesions from week 56 to week 84 in adults with FOP. The OPTIMA extension data were presented at ASBMR on October 12, 2026.
Johnson & Johnson ICOTYDE (icotrokinra) reported two-year Phase 3 ICONIC-LEAD results at Fall Clinical Dermatology 2026. At Week 112, ≥72% of treated adults and adolescents with plaque psoriasis achieved PASI 90, with no new safety signals identified.
